KR102951622B1 - 피라졸 화합물 및 그의 제조 - Google Patents
피라졸 화합물 및 그의 제조Info
- Publication number
- KR102951622B1 KR102951622B1 KR1020207022279A KR20207022279A KR102951622B1 KR 102951622 B1 KR102951622 B1 KR 102951622B1 KR 1020207022279 A KR1020207022279 A KR 1020207022279A KR 20207022279 A KR20207022279 A KR 20207022279A KR 102951622 B1 KR102951622 B1 KR 102951622B1
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- methyl
- alkyl
- difluoromethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
- B01J23/72—Copper
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/06—Halogens; Compounds thereof
- B01J27/08—Halides
- B01J27/122—Halides of copper
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201811003855 | 2018-02-01 | ||
| IN201811003855 | 2018-02-01 | ||
| IN201811003859 | 2018-02-01 | ||
| IN201811003859 | 2018-02-01 | ||
| IN201711042921 | 2018-05-30 | ||
| IN201711042921 | 2018-05-30 | ||
| PCT/IN2019/050076 WO2019150392A1 (en) | 2018-02-01 | 2019-02-01 | Pyrazole compounds and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200118025A KR20200118025A (ko) | 2020-10-14 |
| KR102951622B1 true KR102951622B1 (ko) | 2026-04-13 |
Family
ID=67478207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207022279A Active KR102951622B1 (ko) | 2018-02-01 | 2019-02-01 | 피라졸 화합물 및 그의 제조 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11873289B2 (https=) |
| EP (1) | EP3746434A4 (https=) |
| JP (1) | JP7402804B2 (https=) |
| KR (1) | KR102951622B1 (https=) |
| CN (1) | CN111670184A (https=) |
| AU (1) | AU2019213854C1 (https=) |
| BR (1) | BR112020015692A2 (https=) |
| CA (1) | CA3090204A1 (https=) |
| IL (1) | IL276410B2 (https=) |
| MA (1) | MA54677A (https=) |
| MX (2) | MX2020008151A (https=) |
| MY (1) | MY209060A (https=) |
| SG (1) | SG11202007328UA (https=) |
| WO (1) | WO2019150392A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3090204A1 (en) | 2018-02-01 | 2019-08-08 | MyoKardia, Inc. | Pyrazole compounds and preparation thereof |
| WO2025244956A1 (en) * | 2024-05-20 | 2025-11-27 | MyoKardia, Inc. | Methods of manufacturing danicamtiv |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016118774A1 (en) | 2015-01-22 | 2016-07-28 | MyoKardia, Inc. | 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007284386A (ja) * | 2006-04-18 | 2007-11-01 | Kumiai Chem Ind Co Ltd | ３−ピラゾリルフェニルスルフィド誘導体及びそれを有効成分として含有する殺虫・殺ダニ・殺線虫剤 |
| US8324178B2 (en) * | 2008-10-31 | 2012-12-04 | The Regents Of The University Of California | Method of treatment using alpha-1-adrenergic agonist compounds |
| EP2714680B1 (en) * | 2011-05-27 | 2015-11-25 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| BR112015004097B1 (pt) | 2012-08-30 | 2020-02-18 | Bayer Cropscience Ag | Procedimento para a descarboxilação de derivados do ácido 3,5-bis (haloalquil) -pirazol-4-carboxílico |
| CN104968664A (zh) | 2012-12-12 | 2015-10-07 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的并环化合物 |
| EP3063134B1 (en) | 2013-11-01 | 2020-08-12 | Srf Limited | Process for the preparation of pyrazole derivatives |
| EP3015458A1 (en) | 2014-11-03 | 2016-05-04 | Bayer CropScience AG | Process for preparing 3,5-bis(haloalkyl)pyrazole derivatives from a,a-dihaloamines and ketimines |
| EP3568390B1 (en) * | 2017-01-10 | 2024-03-06 | Sanford Burnham Prebys Medical Discovery Institute | Small molecule activators of nicotinamide phosphoribosyltransferase (nampt) and uses thereof |
| CN111132964A (zh) | 2017-04-11 | 2020-05-08 | 欧瑞克制药公司 | 糖皮质激素受体调节剂 |
| CA3090204A1 (en) | 2018-02-01 | 2019-08-08 | MyoKardia, Inc. | Pyrazole compounds and preparation thereof |
-
2019
- 2019-02-01 CA CA3090204A patent/CA3090204A1/en active Pending
- 2019-02-01 BR BR112020015692-2A patent/BR112020015692A2/pt active Search and Examination
- 2019-02-01 EP EP19747117.0A patent/EP3746434A4/en active Pending
- 2019-02-01 SG SG11202007328UA patent/SG11202007328UA/en unknown
- 2019-02-01 JP JP2020541983A patent/JP7402804B2/ja active Active
- 2019-02-01 MY MYPI2020003963A patent/MY209060A/en unknown
- 2019-02-01 WO PCT/IN2019/050076 patent/WO2019150392A1/en not_active Ceased
- 2019-02-01 US US16/966,502 patent/US11873289B2/en active Active
- 2019-02-01 MA MA054677A patent/MA54677A/fr unknown
- 2019-02-01 CN CN201980011350.9A patent/CN111670184A/zh active Pending
- 2019-02-01 AU AU2019213854A patent/AU2019213854C1/en active Active
- 2019-02-01 MX MX2020008151A patent/MX2020008151A/es unknown
- 2019-02-01 IL IL276410A patent/IL276410B2/en unknown
- 2019-02-01 KR KR1020207022279A patent/KR102951622B1/ko active Active
-
2020
- 2020-07-31 MX MX2025003379A patent/MX2025003379A/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016118774A1 (en) | 2015-01-22 | 2016-07-28 | MyoKardia, Inc. | 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3746434A1 (en) | 2020-12-09 |
| IL276410B2 (en) | 2024-09-01 |
| IL276410A (en) | 2020-09-30 |
| MX2020008151A (es) | 2020-09-18 |
| US11873289B2 (en) | 2024-01-16 |
| AU2019213854C1 (en) | 2023-12-14 |
| US20210053940A1 (en) | 2021-02-25 |
| SG11202007328UA (en) | 2020-08-28 |
| MX2025003379A (es) | 2025-05-02 |
| MA54677A (fr) | 2021-11-17 |
| MY209060A (en) | 2025-06-18 |
| KR20200118025A (ko) | 2020-10-14 |
| CA3090204A1 (en) | 2019-08-08 |
| EP3746434A4 (en) | 2021-11-17 |
| AU2019213854B2 (en) | 2023-06-15 |
| JP7402804B2 (ja) | 2023-12-21 |
| CN111670184A (zh) | 2020-09-15 |
| JP2021512127A (ja) | 2021-05-13 |
| AU2019213854A1 (en) | 2020-09-03 |
| BR112020015692A2 (pt) | 2020-12-08 |
| WO2019150392A1 (en) | 2019-08-08 |
| IL276410B1 (en) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230219922A1 (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| CN101321522B (zh) | 环氧丁醇中间体的制备方法 | |
| IL301897A (en) | PROCESSES OF PREPARING 3-FLUORO-5-(((1S,2AR)-1,3,3,4,4-PENTAFLUORO-2A-HYDROXY-2,2A,3,4-TETRAHYDROSquire Patton Boggs (US) LLP - L.A.1H-CYCLOPENTA[CD]INDEN-7-YL)OXY)-BENZONITRILE | |
| KR102951622B1 (ko) | 피라졸 화합물 및 그의 제조 | |
| JP2017516822A (ja) | デュオカルマイシンのプロドラッグを製造するための改良された方法 | |
| JP3662761B2 (ja) | フェノキシアルキルハライド誘導体の新規製造法 | |
| JP2017025014A (ja) | ベンゾオキサゾール化合物の製造方法 | |
| JP2005526049A (ja) | ベンゾイソキサゾールメタンスルホニルクロリドの調製及びゾニスアミドを形成するためのそのアミド化の方法 | |
| WO2022082337A1 (en) | Process of preparing 3-fluoro-5 ( ( (1r, 2ar) -3, 3, 4, 4-tetrafluoro-1, 2a-dihydroxy-2, 2a, 3, 4-tetrahydro-1h-cyclopenta [cd] inden-7-yl) oxy) benzonitrile | |
| EA044890B1 (ru) | Пиразольные соединения и их получение | |
| HK40027579A (en) | Pyrazole compounds and preparation thereof | |
| CN105980354A (zh) | 有害生物防治剂的制造方法及其中间体 | |
| WO2005026176A1 (ja) | ３−クロロメチル-３-セフェム誘導体の製造方法 | |
| JP2001506255A (ja) | チアゾール類の製造 | |
| JPH0559045A (ja) | ピリジルオキシ誘導体の製造方法 | |
| TW201936597A (zh) | 製備經取代之（１ｈ－１，２，４－三唑－１－基）醇類之方法 | |
| KR20050062940A (ko) | 디이소프로필((1-((2-아미노-6-할로-9ｈ-퓨린-9-일)메틸)사이클로프로필)옥시)-메틸포스포네이트의 새로운 제조방법 | |
| JP2004115476A (ja) | （ｒ）−３−ハロゲノ−２−メチルプロパノールの製造方法 | |
| KR20070090937A (ko) | 2-(피라졸-1-일)피리딘 유도체 | |
| JP2020015686A (ja) | トルバプタン、その塩またはそれらの溶媒和物の製造方法 | |
| KR20190016208A (ko) | 신규의 설폰아마이드 중간체 및 이를 사용한 실로도신의 제조방법 | |
| WO2014114352A1 (en) | Process for making etoricoxib |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| F13 | Ip right granted in full following pre-grant review |
Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |